efbemalenograstim alfa-vuxw (Ryzneuta)
efbemalenograstim alfa-vuxw is an FDA-licensed reference biologic from Evive Biotechnology Singapore PTE. LTD.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2023
Reference approved
Reference product
Ryzneuta efbemalenograstim alfa-vuxw
Evive Biotechnology Singapore PTE. LTD.
- Approved
- Nov 16, 2023
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for efbemalenograstim alfa-vuxw, in chronological order.
Reference approval
Approval date of the reference efbemalenograstim alfa-vuxw product.
2 yr 7 mo ago
Frequently asked questions
Are there biosimilars approved for efbemalenograstim alfa-vuxw (Ryzneuta)?
No 351(k) biosimilars or interchangeable biosimilars referencing efbemalenograstim alfa-vuxw are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.